MedTrace Logo

Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists

NCT01548417 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2016-06-24

Study results available
· View outcomes & findings →

Summary

The primary hypotheses under test are that alcohol dependent subjects treated with mifepristone will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.

Conditions

  • Alcoholism

Interventions

DRUG

Korlym (mifepristone)

600 mg/day, oral pill, 7 days

DRUG

Sugar Pill

600 mg/day, oral pill, 7 days

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • The Scripps Research Institute

    lead OTHER

Principal Investigators

  • Barbara J Mason, PhD · The Scripps Research Institute

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01548417 on ClinicalTrials.gov